Comparative Pharmacology
Head-to-head clinical analysis: BUSULFAN versus DACARBAZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUSULFAN versus DACARBAZINE.
BUSULFAN vs DACARBAZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Busulfan is a bifunctional alkylating agent that crosslinks DNA, primarily at guanine N7 positions, leading to DNA strand breaks and inhibition of DNA replication and transcription. It is cell cycle phase-nonspecific.
Alkylating agent; inhibits DNA and RNA synthesis by forming covalent bonds with DNA, leading to cross-linking and strand breaks. Also inhibits purine synthesis and has some activity as a methylating agent.
1-4 mg/day orally for remission induction in CML; 0.8-1 mg/kg every 6 hours orally for 4 days as part of myeloablative conditioning with cyclophosphamide.
2.4-4.5 mg/kg IV daily for 10 days every 28 days; or 250 mg/m2 IV daily for 5 days every 21 days; or 375-450 mg/m2 IV single dose every 21-28 days.
None Documented
None Documented
Clinical Note
moderateBusulfan + Digoxin
"Busulfan may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateDacarbazine + Digoxin
"Dacarbazine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateBusulfan + Digitoxin
"Busulfan may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateDacarbazine + Digitoxin
"Dacarbazine may decrease the cardiotoxic activities of Digitoxin."
Terminal elimination half-life is 2.5 to 4 hours (mean ~2.6 hours) after oral administration; prolonged to 3-5 hours with high-dose regimens. Half-life may increase with hepatic impairment.
Terminal half-life: 5 hours (range 3-8 h) after IV administration; biphasic decay with initial half-life ~19 min.
Renal (10-50% unchanged), hepatic metabolism (primarily via glutathione S-transferases) with metabolites excreted in bile and urine. Fecal excretion minimal (<5%).
Renal: 40-50% unchanged; hepatic: 30-50% as metabolites (primarily 5-aminoimidazole-4-carboxamide); <10% fecal.
Category C
Category D/X
Alkylating Agent
Alkylating Agent